KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Liabilities (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Total Liabilities data on record, last reported at $336.8 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 25.97% year-over-year to $336.8 million; the TTM value through Dec 2025 reached $336.8 million, down 25.97%, while the annual FY2025 figure was $336.8 million, 25.97% down from the prior year.
  • Total Liabilities reached $336.8 million in Q4 2025 per ACAD's latest filing, down from $413.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $455.0 million in Q4 2024 and bottomed at $150.7 million in Q3 2021.
  • Average Total Liabilities over 5 years is $282.2 million, with a median of $275.7 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 69.27% in 2023, then fell 25.97% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $159.2 million in 2021, then increased by 17.69% to $187.4 million in 2022, then soared by 69.27% to $317.2 million in 2023, then soared by 43.43% to $455.0 million in 2024, then fell by 25.97% to $336.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $336.8 million in Q4 2025, $413.5 million in Q3 2025, and $403.2 million in Q2 2025.